WT1
Basic information
Region (hg38): 11:32387775-32435564
Previous symbols: [ "GUD" ]
Links
Phenotypes
GenCC
Source:
- Denys-Drash syndrome (Definitive), mode of inheritance: AD
- Frasier syndrome (Definitive), mode of inheritance: AD
- Wilms tumor 1 (Strong), mode of inheritance: AD
- familial idiopathic steroid-resistant nephrotic syndrome (Supportive), mode of inheritance: AD
- Frasier syndrome (Supportive), mode of inheritance: AD
- Wilms tumor 1 (Definitive), mode of inheritance: AD
- Denys-Drash syndrome (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Denys-Drash syndrome; Wilms tumor, type 1; Frasier syndrome; Meacham syndrome | AD | Cardiovascular; Oncologic; Renal | Individuals are at risk for several types of neoplasm, and surveillance may allow early detection and treatment for common oncologic features (eg, Wilms tumor, gonadoblastoma); Renal transplant may be indicated (and beneficial) in individuals with end-stage renal faiure; Meacham syndrome can involve congenital cardiac anomalies, and awareness may allow early management | Cardiovascular; Endocrine; Genitourinary; Oncologic; Renal; Pulmonary | 14149008; 4292870; 4316066; 4153449; 331956; 3000666; 3130865; 3026952; 2172500; 1655284; 1338906; 1338905; 8386697; 8071974; 7645607; 7607640; 9398852; 9108089; 9529364; 9607189; 11241056; 12050205; 17853480; 18203154; 18688870; 20150449; 20301471; 21434831; 21559934; 21614510; 22585769; 22876585; 24161391 |
ClinVar
This is a list of variants' phenotypes submitted to
- Frasier syndrome;Drash syndrome;Wilms tumor 1;11p partial monosomy syndrome (13 variants)
- not provided (11 variants)
- Drash syndrome;Wilms tumor 1;11p partial monosomy syndrome;Frasier syndrome (9 variants)
- Drash syndrome (9 variants)
- Wilms tumor 1 (9 variants)
- WT1-related disorder (7 variants)
- Wilms tumor 1;11p partial monosomy syndrome;Frasier syndrome;Drash syndrome (6 variants)
- Drash syndrome;Frasier syndrome;Wilms tumor 1;11p partial monosomy syndrome (5 variants)
- Nephrotic syndrome, type 4 (5 variants)
- 8 conditions (4 variants)
- Frasier syndrome (3 variants)
- Drash syndrome;11p partial monosomy syndrome;Wilms tumor 1;Frasier syndrome (2 variants)
- Focal segmental glomerulosclerosis (1 variants)
- Inborn genetic diseases (1 variants)
- Wilms tumor 1;Frasier syndrome;Drash syndrome;11p partial monosomy syndrome (1 variants)
- Drash syndrome;Frasier syndrome;Wilms tumor 1 (1 variants)
- Drash syndrome;Frasier syndrome (1 variants)
- Meacham syndrome (1 variants)
- Familial idiopathic steroid-resistant nephrotic syndrome (1 variants)
- Wilms tumor 1;11p partial monosomy syndrome;Drash syndrome;Frasier syndrome (1 variants)
- Nephrotic syndrome, type 4;Wilms tumor 1;Frasier syndrome;Drash syndrome (1 variants)
- 11p partial monosomy syndrome;Wilms tumor 1;Frasier syndrome;Drash syndrome (1 variants)
- WT1-related Wilms tumor (1 variants)
- Nephroblastoma (1 variants)
- Frasier syndrome;Wilms tumor 1;Drash syndrome;11p partial monosomy syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the WT1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 345 | 357 | ||||
missense | 25 | 720 | 759 | |||
nonsense | 20 | 30 | ||||
start loss | 0 | |||||
frameshift | 27 | 40 | ||||
inframe indel | 16 | 16 | ||||
splice donor/acceptor (+/-2bp) | 13 | |||||
splice region | 1 | 2 | 24 | 42 | 1 | 70 |
non coding | 50 | 157 | 36 | 245 | ||
Total | 59 | 41 | 811 | 504 | 45 |
Highest pathogenic variant AF is 0.0000131
Variants in WT1
This is a list of pathogenic ClinVar variants found in the WT1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-32387819-A-T | Meacham syndrome • Wilms tumor 1 • Nephrotic syndrome, type 4 | Benign/Likely benign (Jan 13, 2018) | ||
11-32387833-A-G | Nephrotic syndrome, type 4 • Meacham syndrome • Wilms tumor 1 | Uncertain significance (Jan 13, 2018) | ||
11-32387849-T-C | Wilms tumor 1 • Meacham syndrome • Nephrotic syndrome, type 4 | Benign/Likely benign (Jan 12, 2018) | ||
11-32387891-A-C | Meacham syndrome • Wilms tumor 1 • Nephrotic syndrome, type 4 | Uncertain significance (Jan 12, 2018) | ||
11-32387926-T-A | Meacham syndrome • Nephrotic syndrome, type 4 • Wilms tumor 1 | Benign/Likely benign (Jan 13, 2018) | ||
11-32387960-G-A | Nephrotic syndrome, type 4 • Meacham syndrome • Wilms tumor 1 | Benign/Likely benign (Jan 12, 2018) | ||
11-32387992-A-C | Wilms tumor 1 • Meacham syndrome • Nephrotic syndrome, type 4 | Uncertain significance (Jan 13, 2018) | ||
11-32388000-C-A | Nephroblastoma • Meacham syndrome • Nephrotic syndrome, type 4 • 11p partial monosomy syndrome | Uncertain significance (Jun 14, 2016) | ||
11-32388003-AACAC-A | Nephroblastoma • 11p partial monosomy syndrome • Meacham syndrome • Nephrotic syndrome, type 4 | Uncertain significance (Jun 14, 2016) | ||
11-32388003-AACACAC-A | Nephroblastoma • Nephrotic syndrome, type 4 • 11p partial monosomy syndrome • Meacham syndrome | Uncertain significance (Jun 14, 2016) | ||
11-32388003-A-AAC | 11p partial monosomy syndrome • Meacham syndrome • Nephrotic syndrome, type 4 • Nephroblastoma | Uncertain significance (Jun 14, 2016) | ||
11-32388003-A-AACAC | Nephroblastoma • Meacham syndrome • 11p partial monosomy syndrome • Nephrotic syndrome, type 4 | Uncertain significance (Jun 14, 2016) | ||
11-32388003-A-AACACAC | Nephroblastoma • Nephrotic syndrome, type 4 • Meacham syndrome • 11p partial monosomy syndrome | Uncertain significance (Jun 14, 2016) | ||
11-32388008-AC-A | Nephroblastoma • Meacham syndrome • Nephrotic syndrome, type 4 | Benign (Jun 14, 2016) | ||
11-32388079-A-AT | Meacham syndrome • Nephroblastoma • Nephrotic syndrome, type 4 | Benign (Jun 14, 2016) | ||
11-32388155-C-T | Wilms tumor 1 • Nephrotic syndrome, type 4 • Meacham syndrome | Benign/Likely benign (Jan 12, 2018) | ||
11-32388161-C-G | Meacham syndrome • 11p partial monosomy syndrome • Nephrotic syndrome, type 4 • Nephroblastoma | Likely benign (Jun 14, 2016) | ||
11-32388194-A-C | Nephrotic syndrome, type 4 • Wilms tumor 1 • Meacham syndrome | Benign/Likely benign (Jan 13, 2018) | ||
11-32388194-A-T | Nephrotic syndrome, type 4 • Wilms tumor 1 • Meacham syndrome | Benign/Likely benign (Jan 12, 2018) | ||
11-32388217-G-T | Nephroblastoma • 11p partial monosomy syndrome • Nephrotic syndrome, type 4 • Meacham syndrome | Uncertain significance (Jun 14, 2016) | ||
11-32388223-T-C | Wilms tumor 1 • Meacham syndrome • Nephrotic syndrome, type 4 | Benign/Likely benign (Jan 13, 2018) | ||
11-32388238-C-G | Wilms tumor 1 • Nephrotic syndrome, type 4 • Meacham syndrome | Benign (Jan 13, 2018) | ||
11-32388273-G-T | Nephrotic syndrome, type 4 • Meacham syndrome • Wilms tumor 1 | Uncertain significance (Jan 12, 2018) | ||
11-32388290-T-G | Meacham syndrome • Nephrotic syndrome, type 4 • 11p partial monosomy syndrome • Nephroblastoma | Uncertain significance (Jun 14, 2016) | ||
11-32388317-C-A | 11p partial monosomy syndrome • Meacham syndrome • Nephroblastoma • Nephrotic syndrome, type 4 | Uncertain significance (Jun 14, 2016) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
WT1 | protein_coding | protein_coding | ENST00000332351 | 10 | 47856 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.996 | 0.00352 | 125743 | 0 | 5 | 125748 | 0.0000199 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.78 | 201 | 286 | 0.704 | 0.0000155 | 3341 |
Missense in Polyphen | 72 | 127.08 | 0.56659 | 1496 | ||
Synonymous | -0.0334 | 120 | 120 | 1.00 | 0.00000649 | 1017 |
Loss of Function | 4.31 | 2 | 25.5 | 0.0785 | 0.00000139 | 273 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000163 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000879 | 0.00000879 |
Middle Eastern | 0.000163 | 0.000109 |
South Asian | 0.0000980 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Transcription factor that plays an important role in cellular development and cell survival (PubMed:7862533). Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3' (PubMed:7862533, PubMed:17716689, PubMed:25258363). Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. Function may be isoform-specific: isoforms lacking the KTS motif may act as transcription factors (PubMed:15520190). Isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing (PubMed:16934801). Isoform 1 has lower affinity for DNA, and can bind RNA (PubMed:19123921). {ECO:0000269|PubMed:15520190, ECO:0000269|PubMed:16934801, ECO:0000269|PubMed:17716689, ECO:0000269|PubMed:19123921, ECO:0000269|PubMed:19416806, ECO:0000269|PubMed:25258363, ECO:0000269|PubMed:7862533}.;
- Disease
- DISEASE: Frasier syndrome (FS) [MIM:136680]: Characterized by a slowly progressing nephropathy leading to renal failure in adolescence or early adulthood, male pseudohermaphroditism, and no Wilms tumor. As for histological findings of the kidneys, focal glomerular sclerosis is often observed. There is phenotypic overlap with Denys-Drash syndrome. Inheritance is autosomal dominant. {ECO:0000269|PubMed:10571943}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Wilms tumor 1 (WT1) [MIM:194070]: Embryonal malignancy of the kidney that affects approximately 1 in 10'000 infants and young children. It occurs both in sporadic and hereditary forms. {ECO:0000269|PubMed:1317572, ECO:0000269|PubMed:15150775, ECO:0000269|PubMed:9108089, ECO:0000269|PubMed:9529364}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Denys-Drash syndrome (DDS) [MIM:194080]: Typical nephropathy characterized by diffuse mesangial sclerosis, genital abnormalities, and/or Wilms tumor. There is phenotypic overlap with WAGR syndrome and Frasier syndrome. Inheritance is autosomal dominant, but most cases are sporadic. {ECO:0000269|PubMed:10738002, ECO:0000269|PubMed:10799199, ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:11519891, ECO:0000269|PubMed:1302008, ECO:0000269|PubMed:1338906, ECO:0000269|PubMed:15349765, ECO:0000269|PubMed:1655284, ECO:0000269|PubMed:8111391, ECO:0000269|PubMed:8112732, ECO:0000269|PubMed:8295405, ECO:0000269|PubMed:8388765, ECO:0000269|PubMed:8411073, ECO:0000269|PubMed:8741319, ECO:0000269|PubMed:8956030, ECO:0000269|PubMed:9475094, ECO:0000269|PubMed:9529364}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Nephrotic syndrome 4 (NPHS4) [MIM:256370]: A form of nephrotic syndrome, a renal disease clinically characterized by severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show non-specific histologic changes such as focal segmental glomerulosclerosis and diffuse mesangial proliferation. Some affected individuals have an inherited steroid-resistant form and progress to end-stage renal failure. Most patients with NPHS4 show diffuse mesangial sclerosis on renal biopsy, which is a pathologic entity characterized by mesangial matrix expansion with no mesangial hypercellularity, hypertrophy of the podocytes, vacuolized podocytes, thickened basement membranes, and diminished patency of the capillary lumen. {ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:15253707, ECO:0000269|PubMed:20798252, ECO:0000269|PubMed:9529364, ECO:0000269|PubMed:9607189}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Meacham syndrome (MEACHS) [MIM:608978]: Rare sporadically occurring multiple malformation syndrome characterized by male pseudohermaphroditism with abnormal internal female genitalia comprising a uterus and double or septate vagina, complex congenital heart defect and diaphragmatic abnormalities. {ECO:0000269|PubMed:17853480}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving WT1 may be a cause of desmoplastic small round cell tumor (DSRCT). Translocation t(11;22)(p13;q12) with EWSR1.; DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle- shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. {ECO:0000269|PubMed:8401592}. Note=The disease may be caused by mutations affecting the gene represented in this entry.;
- Pathway
- Transcriptional misregulation in cancer - Homo sapiens (human);Primary Focal Segmental Glomerulosclerosis FSGS;chaperones modulate interferon signaling pathway;overview of telomerase protein component gene htert transcriptional regulation;p73 transcription factor network;TGF-beta super family signaling pathway canonical;BMP2 signaling TGF-beta MV;BMP signaling Dro;Regulation of Telomerase
(Consensus)
Recessive Scores
- pRec
- 0.875
Intolerance Scores
- loftool
- rvis_EVS
- -0.45
- rvis_percentile_EVS
- 24
Haploinsufficiency Scores
- pHI
- 0.999
- hipred
- hipred_score
- ghis
- 0.494
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.991
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Wt1
- Phenotype
- immune system phenotype; renal/urinary system phenotype; embryo phenotype; respiratory system phenotype; liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; endocrine/exocrine gland phenotype; neoplasm; muscle phenotype; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype;
Zebrafish Information Network
- Gene name
- wt1a
- Affected structure
- podocyte
- Phenotype tag
- abnormal
- Phenotype quality
- flattened
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;vasculogenesis;ureteric bud development;branching involved in ureteric bud morphogenesis;kidney development;regulation of animal organ formation;regulation of transcription, DNA-templated;regulation of transcription by RNA polymerase II;germ cell development;thorax and anterior abdomen determination;heart development;sex determination;negative regulation of cell population proliferation;RNA splicing;gonad development;male gonad development;tissue development;positive regulation of gene expression;negative regulation of cell growth;adrenal gland development;male genitalia development;epithelial cell differentiation;glomerulus development;glomerular basement membrane development;adrenal cortex formation;camera-type eye development;negative regulation of apoptotic process;negative regulation of transcription, DNA-templated;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;mesenchymal to epithelial transition;positive regulation of heart growth;diaphragm development;cardiac muscle cell fate commitment;visceral serous pericardium development;cellular response to cAMP;cellular response to gonadotropin stimulus;metanephric mesenchyme development;glomerular visceral epithelial cell differentiation;posterior mesonephric tubule development;metanephric epithelium development;metanephric S-shaped body morphogenesis;negative regulation of metanephric glomerular mesangial cell proliferation;positive regulation of pri-miRNA transcription by RNA polymerase II;positive regulation of DNA methylation;positive regulation of male gonad development;negative regulation of female gonad development;positive regulation of metanephric ureteric bud development
- Cellular component
- nucleus;nucleoplasm;nucleolus;cytoplasm;cytosol;nuclear speck
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA-binding transcription factor activity;RNA binding;protein binding;zinc ion binding;double-stranded methylated DNA binding;sequence-specific DNA binding;transcription regulatory region DNA binding;hemi-methylated DNA-binding;C2H2 zinc finger domain binding